Giovannini, Catia
Salzano, Anna Maria
Baglioni, Michele
Vitale, Monica
Scaloni, Andrea
Zambrano, Nicola
Giannone, Ferdinando Antonio
Vasuri, Francesco
D’Errico, Antonia
Svegliati Baroni, Gianluca
Bolondi, Luigi
Gramantieri, Laura
Article History
Received: 12 June 2018
Revised: 3 December 2018
Accepted: 14 December 2018
First Online: 15 February 2019
Competing interests
: The authors declare no competing interests.
: The study was conducted according to the Good Clinical Practice guidelines and the Declaration of Helsinki. The protocol was approved by local ethic committee and written informed consent was obtained for all patients.
: This study was supported by Bristol-Myers Squibb to L.B. and by Programma di Ricerca Regione-Università 2010–2012, Regione Emilia-Romagna, Bando “Ricerca Innovativa” for the project “Innovative approaches to the diagnosis and pharmacogenetic-based therapies of primary hepatic tumours, peripheral B and T-cell lymphomas and lymphoblastic leukaemias” to L.B. and L.G. This study was supported by PO FESR 2014-2020 o.s. 1.2, Regione Campania, Bando “Manifestazione di interesse per la realizzazione di Technology Platforms nell’ambito della lotta alle Patologie oncologiche” for the project “Sviluppo di approcci terapeutici innovative per patologie neoplastiche resistenti ai trattamenti (SATIN)” to A.S.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).